Call 911 or seek emergency medical care immediately if you experience: Signs of severe allergic reaction (anaphylaxis), including difficulty breathing, severe rash, swelling of the face or throat, or rapid heartbeat Severe, persistent abdominal pain, particularly if radiating to the back, which may indicate pancreatitis (stop taking semaglutide) Suicidal thoughts or behaviors (alternatively, call or text 988 Suicide & Crisis Lifeline) Persistent vomiting that prevents you from keeping down fluids, risking dehydration Contact your healthcare provider within 24 hours if you notice: Right upper abdominal pain, fever, or yellowing of skin/eyes, which may indicate gallbladder disease Sudden changes in vision, floaters, or vision loss, especially if you have diabetic retinopathy Severe abdominal bloating, inability to pass gas or stool, which may suggest intestinal obstruction (ileus) Signs of dehydration or possible kidney problems, including dark urine, dizziness, or decreased urination Moderate to severe nausea that interferes with eating or drinking Symptoms of hypoglycemia (particularly if taking insulin or sulfonylureas), such as shakiness, confusion, sweating, or rapid heartbeat Unexplained persistent fatigue or weakness Routine follow-up is appropriate for mild, tolerable side effects that do not interfere with daily activities

What This Means for Physicians and Patients These agreements have the potential to: Improve affordability and access to GLP-1 therapies for Medicare and some Medicaid beneficiaries Increase utilization of GLP-1 drugs for obesity and related conditions Raise important questions about long-term health care spending, equity, and sustainability As implementation details emerge, it will be important for clinicians, health systems, and policymakers to closely monitor the effects of these changes on patient outcomes, payer budgets, and access across different populations
There is the long-term value, too
Low routine disruptors are good at staying lean